Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006092 · ClinicalTrials.gov registry record · Phase 2
Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00006092 is a Phase 2 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 2 participants.
The verdict
NCT00006092, a Phase 2 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have recurrent or refractory acute lymphoblastic leukemia or chronic myelogenous leukemia.
Interventions
- DRUG Arsenic Trioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2000-08 |
| Est. Completion | 2003-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006092
The ClinicalTrials.gov registry entry for NCT00006092 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Arsenic Trioxide is the first listed.
NCT00006092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006092 about?
NCT00006092 is a clinical study titled "Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have recurrent or refractory acute lymphoblastic leukemia or chronic myelogenous l...
What is the current status of trial NCT00006092?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2000-08. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00006092?
The interventions under investigation include: Arsenic Trioxide (DRUG).
Who is sponsoring clinical trial NCT00006092?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.